HIV R4P is coming!

HIV vaccine highlights and spotlights

HIVR4P fosters interdisciplinary knowledge-exchange on HIV vaccines, microbicides, PrEP, treatment as prevention and biomedical interventions as well as their related social and behavioral implications. The 4th HIV Research for Prevention Conference (HIVR4P // Virtual) will take place on 27-28 January and 3-4 February 2021.

To help attendees manage their time and navigate a busy programme, the Enterprise has developed an HIV vaccine R&D roadmap which covers active immunization and passive immunization with broadly neutralizing antibodies (bNAbs), especially VRC01.

The Enterprise is also sponsoring two live satellites.

We look forward to an exciting conference!

Warm regards,


Wednesday 27 January, 18:45 – 20:15 (UTC) channel 2

HIV & TB: An R&D tale of two vaccines, in partnership with the TuBerculosis Vaccine Initiative (TBVI).

The aim of the satellite is to examine lessons learned from our respective R&D journey and look to a future in which integrated research supports product development. Through two panel discussions and an audience Q&A, we will explore the role of the industry, how to develop mutually beneficial academic-industry relationships, as well as funding structures and mechanisms that create a sustainable R&D environment.

The satellite is supported by three pre-recorded presentations:

  • A view of the HIV pipeline: Kundai Chinyenze, IAVI.
  • A view of the TB pipeline: Katrin Eichelberg, NIAID (NIH)
  • An overview of HIV and TB R&D funding: Mike Frick, TAG.

Visit the Satellite page to find out more.

Wednesday 03 February, 18:45 – 19:45 (UTC) channel 2

Vaccines: What HIV R&D did for COVID-19.

The COVID-19 pandemic is showing that a rapid response to a public health challenge of planetary scale is possible. This remarkable response is benefitting from existing technologies, capacity and capabilities, and especially from previous work on HIV prevention, treatment and cure research.

The satellite will present the findings of report commissioned by the Global HIV Vaccine Enterprise on how investment in HIV vaccine Research and Development (R&D) has enabled the rapid advancement of COVID-19 vaccine R&D.

This event will bring together researchers, clinicians, community members, industry and regulators and aim to raise the visibility and contribution of HIV vaccine R&D to the COVID-19 response to the global community and ensure that innovation arising from COVID-19 vaccine research benefits future HIV vaccines research.

WP Twitter Auto Publish Powered By :